Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IndegeneNSE:INDGN +2.04%50 Return-on-Tangible-Asset is 15.48% as of Jun. 2026, which is 13% below its 10-year median of 17.82. GuruFocus rates NSE:INDGN with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 685 Healthcare Providers & Services companies, Indegene ranks better than 89.34% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Indegene's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹4,648 Mil. Indegene's average total tangible assets for the quarter that ended in Jun. 2026 was ₹30,027 Mil. Therefore, Indegene's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 15.48%.
The historical rank and industry rank for Indegene's Return-on-Tangible-Asset or its related term are showing as below:
NSE:INDGN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 13.66 Med: 17.82 Max: 26.85
Current: 13.66
During the past 6 years, Indegene's highest Return-on-Tangible-Asset was 26.85%. The lowest was 13.66%. And the median was 17.82%.
NSE:INDGN's Return-on-Tangible-Asset is ranked better than 89.34% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 2.61
vs NSE:INDGN: 13.66
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Indegene Return-on-Tangible-Asset Related Terms
Indegene Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Indegene's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDGN vs VEEV, BTSG, HQY: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Indegene's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indegene Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indegene's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Indegene's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.48% mean?
Indegene (NSE:INDGN) has a Return-on-Tangible-Asset of 15.48% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Indegene and its competitors. This is 13% below median its historical median of 17.82. Over the past decade, Indegene's Return-on-Tangible-Asset has ranged from 13.66 to 26.85. According to the industry distribution chart, Indegene ranks #73 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 10.7%.
Is Indegene's Return-on-Tangible-Asset too high?
Indegene's current Return-on-Tangible-Asset of 15.48% is 13% below median its 10-year median of 17.82. Over the past 10 years, this metric has ranged from a low of 13.66 to a high of 26.85. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.61. Indegene's value of 15.48% is 493.1% above this industry median. Based on the distribution chart, Indegene ranks #73 out of 685 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Indegene has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Indegene's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Indegene ranks #73 out of 685 companies for Return-on-Tangible-Asset. This places Indegene in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.61. Indegene's value of 15.48% is 493.1% above this benchmark. Historically, Indegene's own Return-on-Tangible-Asset has ranged from 13.66 to 26.85 over the past decade. While the company's 10-year median is 17.82 vs. the industry median of 2.61, Indegene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.61, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indegene's current Return-on-Tangible-Asset of 15.48% is 493.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Indegene and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indegene's current Return-on-Tangible-Asset is 15.48%, which is 13% below median its own 10-year median of 17.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indegene stock overvalued right now?
Indegene (NSE:INDGN) has a current Return-on-Tangible-Asset of 15.48%. The current Return-on-Tangible-Asset is 15.48%, which is 13% below median its 10-year median of 17.82 and 493.1% above the Healthcare Providers & Services industry median of 2.61. Indegene's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Indegene (NSE:INDGN), the current Return-on-Tangible-Asset is 15.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
50GF Score
Get the complete analysis for NSE:INDGN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDGN has been successfully added to your 
